- Home
- NMT vs ZNTL Comparison
NMT vs ZNTL Comparison
Compare NMT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- ZNTL
- Stock Information
- Founded
- NMT 1993
- ZNTL 2014
- Country
- NMT United States
- ZNTL United States
- Employees
- NMT N/A
- ZNTL N/A
- Industry
- NMT Finance/Investors Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- ZNTL Health Care
- Exchange
- NMT Nasdaq
- ZNTL Nasdaq
- Market Cap
- NMT 106.2M
- ZNTL 105.8M
- IPO Year
- NMT N/A
- ZNTL 2020
- Fundamental
- Price
- NMT $11.19
- ZNTL $1.99
- Analyst Decision
- NMT
- ZNTL Buy
- Analyst Count
- NMT 0
- ZNTL 7
- Target Price
- NMT N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- NMT 19.1K
- ZNTL 784.9K
- Earning Date
- NMT 01-01-0001
- ZNTL 08-06-2025
- Dividend Yield
- NMT 3.21%
- ZNTL N/A
- EPS Growth
- NMT N/A
- ZNTL N/A
- EPS
- NMT N/A
- ZNTL N/A
- Revenue
- NMT N/A
- ZNTL $26,865,000.00
- Revenue This Year
- NMT N/A
- ZNTL N/A
- Revenue Next Year
- NMT N/A
- ZNTL N/A
- P/E Ratio
- NMT N/A
- ZNTL N/A
- Revenue Growth
- NMT N/A
- ZNTL N/A
- 52 Week Low
- NMT $9.05
- ZNTL $1.01
- 52 Week High
- NMT $10.93
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- NMT 37.56
- ZNTL 78.59
- Support Level
- NMT $11.14
- ZNTL $1.55
- Resistance Level
- NMT $11.32
- ZNTL $1.70
- Average True Range (ATR)
- NMT 0.11
- ZNTL 0.12
- MACD
- NMT -0.00
- ZNTL 0.05
- Stochastic Oscillator
- NMT 15.15
- ZNTL 91.43
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.